Don't Sleep On Pfizer: The Turnaround Is Just Getting Started

Core Viewpoint - Pfizer Inc. (NYSE: PFE) has consistently been rated as a "Buy" by analysts, even during periods of stock price decline, indicating strong confidence in the company's long-term prospects [1]. Group 1 - The analyst has been covering Pfizer since November 2021, maintaining a positive outlook despite market fluctuations [1]. - The recent article on Pfizer gained significant attention, suggesting a growing interest in the stock among investors [1]. - The analyst holds a beneficial long position in Pfizer shares, indicating personal investment confidence in the company's performance [1].